OmniAb (OABI) Short-term Investments (2022 - 2026)
OmniAb (OABI) reported Short-term Investments of $20.0 million for Q1 2026, down 38.76% year-over-year from $32.7 million in Q1 2025, and down 29.74% on a QoQ basis from $28.5 million in Q4 2025.
OmniAb (OABI) has 5 years of Short-term Investments data on file, last reported at $20.0 million in Q1 2026.
- Quarterly Short-term Investments fell 38.76% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (down 38.76% YoY) and the FY2025 annual result came in at $28.5 million, down 10.48% from the prior year.
- Short-term Investments declined to $20.0 million in Q1 2026 per OABI's latest filing, from $28.5 million in the prior quarter.
- Across five years, Short-term Investments topped out at $90.7 million in Q1 2023 and bottomed at $20.0 million in Q1 2026.
- The 5-year median for Short-term Investments is $34.6 million (2024), against an average of $47.1 million.
- The widest annual swing landed in 2023, when Short-term Investments increased 28.7%; it then tumbled 57.36% in 2024.
- Tracing OABI's Short-term Investments over 5 years: stood at $54.9 million in 2022, then gained by 28.7% to $70.6 million in 2023, then sank by 54.92% to $31.8 million in 2024, then dropped by 10.48% to $28.5 million in 2025, then dropped by 29.74% to $20.0 million in 2026.
- Per Business Quant, the three latest OABI Short-term Investments figures stand at $20.0 million (Q1 2026), $28.5 million (Q4 2025), and $31.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.03 Mn |
| Dec 31, 2025 | 28.50 Mn |
| Sep 30, 2025 | 30.96 Mn |
| Jun 30, 2025 | 23.33 Mn |
| Mar 31, 2025 | 32.70 Mn |
| Dec 31, 2024 | 31.84 Mn |
| Sep 30, 2024 | 32.15 Mn |
| Jun 30, 2024 | 36.43 Mn |
| Mar 31, 2024 | 49.95 Mn |
| Dec 31, 2023 | 70.63 Mn |
| Sep 30, 2023 | 75.38 Mn |
| Jun 30, 2023 | 82.16 Mn |
| Mar 31, 2023 | 90.70 Mn |
| Dec 31, 2022 | 54.88 Mn |